Download FREE Report Sample
Download Free sampleSpinal muscular atrophy treatment market growth is driven by a significant increase in the number of product launches despite the relative rarity of the disorder and high costs associated with the approved drugs. The treatment of spinal muscular atrophy through the gene therapy drug called Zolgensma
Spinal Muscular Atrophy Therapeutic Market contains market size and forecasts of Spinal Muscular Atrophy (SMA) Therapeutic in Global, including the following market information:
Global Spinal Muscular Atrophy (SMA) Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Spinal Muscular Atrophy (SMA) Therapeutic market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Nusinersen Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Spinal Muscular Atrophy (SMA) Therapeutic include Biogen, Novartis, Roche, Astellas Pharma and Genzyme Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Spinal Muscular Atrophy (SMA) Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spinal Muscular Atrophy (SMA) Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Spinal Muscular Atrophy (SMA) Therapeutic Market Segment Percentages, by Type, 2021 (%)
Nusinersen
Onasemnogen Abeparvovec
Global Spinal Muscular Atrophy (SMA) Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Spinal Muscular Atrophy (SMA) Therapeutic Market Segment Percentages, by Application, 2021 (%)
Type 1 SMA
Type 2 SMA
Other
Global Spinal Muscular Atrophy (SMA) Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Spinal Muscular Atrophy (SMA) Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Spinal Muscular Atrophy (SMA) Therapeutic revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Spinal Muscular Atrophy (SMA) Therapeutic revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Novartis
Roche
Astellas Pharma
Genzyme Corporation
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
